Advertisement
News
Advertisement

Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting

Mon, 03/28/2011 - 5:35am
Bio-Medicine.Org

NEW YORK, March 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that two abstracts on KRX-0401 (perifosine) will be presented at the upcoming 102nd annual meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, from April 2-6, 2011. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma. Both of these Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA, and with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.Sunday, April 3, 2011Abstract #640:

"The Akt inhibitor Perifosine strongly enhances the antitumor and antivascular activity of CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", A. Giacomini, S. L. Locatelli, M. Righi, L. Cleris, P.D. Longoni, M. Milanesi, M. Francolini, M. Magni, M. Di Nicola, A. M. Gianni, C. Carlo-Stella.Date and time:

Sunday, April 3, 2011, 1:00-5:00 p.m. Eastern (Exhibit Hall A4-C)Poster Session ID:

Cellular and Molecular Biology 27Poster Section:

27 Poster Board:

14Monday, April 4, 2011Abstract #1965:

"Antitumor activity of novel Akt inhibitor, perifosine in gastric cell lines.", Tae Soo Kim, Hyo Song Kim, Bo Ram Kwan, Chan Hee Park Park, Hei-Cheul Jeung Jeung, Woo Ick Jang, Juergen Engel, Hyun Cheol Chung, Jae Kyung Roh, Sun Young Rha.Date and time:

Monday, April 4, 2011, 1:00-5:00 p.m. Eastern (Exhibit Hall A4-C)Poster Session ID:

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading